Table 1 Demographic and baseline characteristics
| Â | Part A | Part B | |
|---|---|---|---|
rhACE2 0.1 -> 0.2 -> 0.4 -> 0.8Â mg/kg | Placebo BID | rhACE2 0.4Â mg/kg BID | |
Number of subjects planned | 5 | 30 | 30 |
All subjects population | 5 | 20 | 19 |
Age, years, mean (SD) | 50.8 (17.04) | 50.5(15.44) | 50.6(16.36) |
Sex, n (%) | |||
 Female | 2 (40) | 7 (35) | 6 (32) |
 Male | 3 (60) | 13 (65) | 13 (68) |
BMI, kg/m2, mean (SD) | 31.4 (5.43) | 29.59 (6.896) | 29.21 (4.997) |
Time since ARDS, h | 17.8 (10.8) | 26.899 (13.82) | 26.916 (13.99) |
Glasgow Coma Scale | 6.6 (2.51) | 8.2 (4.47) | 7.1 (3.20) |
SOFA score | 10.8 (2.49) | 7.8 (2.79) | 8.9 (2.36) |
PaO2/FiO2, geometric mean (SD on logarithmic scale) | 140.3 (0.468) | 160.5 (0.523) | 143.6 (0.522) |
PEEP, cmH2O | 14.0 (0.196) | 10.4 (0.438) | 10.4 (0.340) |
Ang II, pg/ml | 26.5 (0.513) | 11.4 (1.834) | 19.6 (1.858) |